Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-26T22:41:21.710Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of Prochlorperazine (Stemetil) in Chronic Psychotic Disorders

Published online by Cambridge University Press:  08 February 2018

John Denham
John Denham*
Affiliation:
Whitchurch Hospital, Cardiff
Get access Rights & Permissions [Opens in a new window]

Extract

Prochlorperazine, 1-[3-(3-chloro-10-phenothiazinyl)propyl]-4-methyl-piperazine dimaleate, a phenothiazine derivative related to chlorpromazine, was discovered in the Rhône Poulenc laboratories, and studied pharmacologically in 1956, by Ducrot and Koetschet, for its anti-emetic properties. Clinical trials, following this experimental evidence, suggested that, as well as possessing powerful anti-emetic properties, the drug was of considerable therapeutic value in migraine, Ménière's syndrome, and vertigo of other origins.

Type
Original Articles
Information
Journal of Mental Science , Volume 104 , Issue 437 , October 1958 , pp. 1190 - 1194
Copyright
Copyright © Royal College of Psychiatrists, 1958 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ducrot, R., and Koetschet, P., “Anti-emetic properties of a new phenothiazine derivative 3-chloro-10-(3-N-methylpiperasinylpropyl)-phenothiasine (6140 R.P.)”, Commn. Int. Physiol., Congr., Brussels, 30 July–4 August, 1956.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.